129 related articles for article (PubMed ID: 7913507)
1. Nonpeptide peptidomimetic antagonists of the neuropeptide Y receptor: benextramine analogs with selectivity for the peripheral Y2 receptor.
Chaurasia C; Misse G; Tessel R; Doughty MB
J Med Chem; 1994 Jul; 37(14):2242-8. PubMed ID: 7913507
[TBL] [Abstract][Full Text] [Related]
2. Benextramine-neuropeptide Y receptor interactions: contribution of the benzylic moieties to [3H]neuropeptide Y displacement activity.
Doughty MB; Chaurasia CS; Li K
J Med Chem; 1993 Jan; 36(2):272-9. PubMed ID: 8093737
[TBL] [Abstract][Full Text] [Related]
3. Benextramine-neuropeptide Y (NPY) binding site interactions: characterization of 3H-NPY binding site heterogeneity in rat brain.
Doughty MB; Li K; Hu L; Chu SS; Tessel R
Neuropeptides; 1992 Nov; 23(3):169-80. PubMed ID: 1470308
[TBL] [Abstract][Full Text] [Related]
4. Characterization of vascular postsynaptic neuropeptide Y receptor function and regulation. 1. NPY-induced constriction in isolated rat femoral artery rings is mediated by both Y1 and Y2 receptors: evidence from benextramine protection studies.
Tessel RE; Miller DW; Misse GA; Dong X; Doughty MB
J Pharmacol Exp Ther; 1993 Apr; 265(1):172-7. PubMed ID: 8474004
[TBL] [Abstract][Full Text] [Related]
5. Effects of neuropeptide Y and [Leu31,Pro34] neuropeptide Y on experimental gastric lesion formation and gastric secretion in the rat.
Penner SB; Smyth DD; Glavin GB
J Pharmacol Exp Ther; 1993 Jul; 266(1):339-43. PubMed ID: 8101219
[TBL] [Abstract][Full Text] [Related]
6. Failure of the putative neuropeptide Y antagonists, benextramine and PYX-2, to inhibit Y2 receptors in rat isolated prostatic vas deferens.
Palea S; Corsi M; Rimland JM; Trist DG; Ratti E
Br J Pharmacol; 1995 Nov; 116(5):2401-6. PubMed ID: 8581275
[TBL] [Abstract][Full Text] [Related]
7. Discrimination by benextramine between the NPY-Y1 receptor subtypes present in rabbit isolated vas deferens and saphenous vein.
Palea S; Corsi M; Rimland JM; Trist DG
Br J Pharmacol; 1995 May; 115(1):3-10. PubMed ID: 7647980
[TBL] [Abstract][Full Text] [Related]
8. Ligand binding and functional effects of systematic double D-amino acid residue substituted neuropeptide Y analogs on Y1 and Y2 receptor types.
Grundemar L; Kahl U; Callréus T; Langel U; Bienert M; Beyermann M
Regul Pept; 1996 Apr; 62(2-3):131-6. PubMed ID: 8795076
[TBL] [Abstract][Full Text] [Related]
9. Role of sulfhydryl groups in Y2 neuropeptide Y receptor binding activity.
Li W; MacDonald RG; Hexum TD
J Biol Chem; 1992 Apr; 267(11):7570-5. PubMed ID: 1348506
[TBL] [Abstract][Full Text] [Related]
10. Binding profile of benextramine at neuropeptide Y receptor subtypes in rat brain areas.
Melchiorre C; Romualdi P; Bolognesi ML; Donatini A; Ferri S
Eur J Pharmacol; 1994 Nov; 265(1-2):93-8. PubMed ID: 7883034
[TBL] [Abstract][Full Text] [Related]
11. Subtype selectivity and antagonistic profile of the nonpeptide Y1 receptor antagonist BIBP 3226.
Wieland HA; Willim KD; Entzeroth M; Wienen W; Rudolf K; Eberlein W; Engel W; Doods HN
J Pharmacol Exp Ther; 1995 Oct; 275(1):143-9. PubMed ID: 7562543
[TBL] [Abstract][Full Text] [Related]
12. Evidence that the inhibition of luteinizing hormone secretion exerted by central administration of neuropeptide Y (NPY) in the rat is predominantly mediated by the NPY-Y5 receptor subtype.
Raposinho PD; Broqua P; Pierroz DD; Hayward A; Dumont Y; Quirion R; Junien JL; Aubert ML
Endocrinology; 1999 Sep; 140(9):4046-55. PubMed ID: 10465275
[TBL] [Abstract][Full Text] [Related]
13. Characterization of neuropeptide Y (NPY) receptors in human cerebral arteries with selective agonists and the new Y1 antagonist BIBP 3226.
Abounader R; Villemure JG; Hamel E
Br J Pharmacol; 1995 Oct; 116(4):2245-50. PubMed ID: 8564255
[TBL] [Abstract][Full Text] [Related]
14. Vasoconstrictor effects of various neuropeptide Y analogues on the rat tail artery in the presence of phenylephrine.
Tschöpl M; Miller RC; Pelton J; Stoclet JC; Bucher B
Br J Pharmacol; 1993 Nov; 110(3):1098-104. PubMed ID: 8298798
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of sympathetic vasoconstriction in pigs in vivo by the neuropeptide Y-Y1 receptor antagonist BIBP 3226.
Lundberg JM; Modin A
Br J Pharmacol; 1995 Dec; 116(7):2971-82. PubMed ID: 8680732
[TBL] [Abstract][Full Text] [Related]
16. The non-peptide neuropeptide Y Y1 receptor antagonist BIBP3226 blocks the [Leu31,Pro34]neuropeptide Y-induced modulation of alpha 2-adrenoceptors in the nucleus tractus solitarii of the rat.
Yang SN; Finnman UB; Fuxe K
Neuroreport; 1996 Nov; 7(15-17):2701-5. PubMed ID: 8981451
[TBL] [Abstract][Full Text] [Related]
17. C-terminal modifications of neuropeptide Y and its analogs leading to selectivity for the mouse brain receptor over the porcine spleen receptor.
Krstenansky JL; Owen TJ; Payne MH; Shatzer SA; Buck SH
Neuropeptides; 1990 Nov; 17(3):117-20. PubMed ID: 1964720
[TBL] [Abstract][Full Text] [Related]
18. Functional effects and ligand binding of chimeric galanin-neuropeptide Y (NPY) peptides on NPY and galanin receptor types.
Kahl U; Langel U; Bartfai T; Grundemar L
Br J Pharmacol; 1994 Apr; 111(4):1129-34. PubMed ID: 7518295
[TBL] [Abstract][Full Text] [Related]
19. Activation of neuropeptide Y1 and neuropeptide Y2 receptors by substituted and truncated neuropeptide Y analogs: identification of signal epitopes.
Grundemar L; Krstenansky JL; Håkanson R
Eur J Pharmacol; 1993 Mar; 232(2-3):271-8. PubMed ID: 8467862
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a new neuropeptide Y Y5 agonist radioligand: [125I][cPP(1-7), NPY(19-23), Ala31, Aib32, Gln34]hPP.
Dumont Y; Thakur M; Beck-Sickinger A; Fournier A; Quirion R
Neuropeptides; 2004 Aug; 38(4):163-74. PubMed ID: 15337369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
